Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neurometrix Inc (NURO)

Neurometrix Inc (NURO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,264
  • Shares Outstanding, K 1,987
  • Annual Sales, $ 5,900 K
  • Annual Income, $ -6,530 K
  • 60-Month Beta 2.26
  • Price/Sales 1.35
  • Price/Cash Flow N/A
  • Price/Book 0.31
Trade NURO with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.58 +18.66%
on 03/05/24
4.30 -1.16%
on 02/29/24
-0.02 (-0.47%)
since 02/28/24
3-Month
2.70 +57.41%
on 02/22/24
4.42 -3.85%
on 02/28/24
+0.47 (+12.43%)
since 12/28/23
52-Week
2.70 +57.41%
on 02/22/24
12.04 -64.70%
on 04/11/23
-7.19 (-62.85%)
since 03/28/23

Most Recent Stories

More News
NeuroMetrix Reports Q2 2022 Financial Results

WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and...

NURO : 4.25 (+2.16%)
NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter...

NURO : 4.25 (+2.16%)
NeuroMetrix Appoints Brad Fluegel to its Board of Directors

WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of...

NURO : 4.25 (+2.16%)
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo...

NURO : 4.25 (+2.16%)
NeuroMetrix Reports Q1 2022 Financial Results

WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended...

NURO : 4.25 (+2.16%)
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter...

NURO : 4.25 (+2.16%)
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome

WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will...

NURO : 4.25 (+2.16%)
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results

WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and...

NURO : 4.25 (+2.16%)
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call

WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full...

NURO : 4.25 (+2.16%)
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough...

NURO : 4.25 (+2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Neurometrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes,...

See More

Key Turning Points

3rd Resistance Point 4.47
2nd Resistance Point 4.37
1st Resistance Point 4.31
Last Price 4.25
1st Support Level 4.15
2nd Support Level 4.06
3rd Support Level 4.00

See More

52-Week High 12.04
Fibonacci 61.8% 8.47
Fibonacci 50% 7.37
Fibonacci 38.2% 6.27
Last Price 4.25
52-Week Low 2.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar